Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 132

1.

Diagnostic accuracy and predictive value of extended autoantibody profile in systemic sclerosis.

Villalta D, Imbastaro T, Di Giovanni S, Lauriti C, Gabini M, Turi MC, Bizzaro N.

Autoimmun Rev. 2012 Dec;12(2):114-20. doi: 10.1016/j.autrev.2012.07.005. Review.

PMID:
22776784
2.

Anti-centromere antibodies in a large cohort of systemic sclerosis patients: comparison between immunofluorescence, CENP-A and CENP-B ELISA.

Mahler M, You D, Baron M, Taillefer SS, Hudson M; Canadian Scleroderma Research Group(CSRG)., Fritzler MJ.

Clin Chim Acta. 2011 Oct 9;412(21-22):1937-43. doi: 10.1016/j.cca.2011.06.041.

PMID:
21756890
3.

Frequency of disease-associated and other nuclear autoantibodies in patients of the German Network for Systemic Scleroderma: correlation with characteristic clinical features.

Mierau R, Moinzadeh P, Riemekasten G, Melchers I, Meurer M, Reichenberger F, Buslau M, Worm M, Blank N, Hein R, Müller-Ladner U, Kuhn A, Sunderkötter C, Juche A, Pfeiffer C, Fiehn C, Sticherling M, Lehmann P, Stadler R, Schulze-Lohoff E, Seitz C, Foeldvari I, Krieg T, Genth E, Hunzelmann N.

Arthritis Res Ther. 2011;13(5):R172. doi: 10.1186/ar3495.

4.

Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud's phenomenon to systemic sclerosis: a twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis.

Koenig M, Joyal F, Fritzler MJ, Roussin A, Abrahamowicz M, Boire G, Goulet JR, Rich E, Grodzicky T, Raymond Y, Senécal JL.

Arthritis Rheum. 2008 Dec;58(12):3902-12. doi: 10.1002/art.24038.

5.

Detection of anti-U3-RNP/fibrillarin IgG antibodies by line immunoblot assay has comparable clinical significance to immunoprecipitation testing in systemic sclerosis.

Peterson LK, Jaskowski TD, Mayes MD, Tebo AE.

Immunol Res. 2016 Apr;64(2):483-8. doi: 10.1007/s12026-015-8710-9.

PMID:
26467972
6.

Interpretation of an Extended Autoantibody Profile in a Well-Characterized Australian Systemic Sclerosis (Scleroderma) Cohort Using Principal Components Analysis.

Patterson KA, Roberts-Thomson PJ, Lester S, Tan JA, Hakendorf P, Rischmueller M, Zochling J, Sahhar J, Nash P, Roddy J, Hill C, Nikpour M, Stevens W, Proudman SM, Walker JG.

Arthritis Rheumatol. 2015 Dec;67(12):3234-44. doi: 10.1002/art.39316.

7.

Clinical and serological heterogeneity in patients with anticentromere antibodies.

Miyawaki S, Asanuma H, Nishiyama S, Yoshinaga Y.

J Rheumatol. 2005 Aug;32(8):1488-94.

PMID:
16078324
8.

Clinical and serological associations with anti-RNA polymerase antibodies in systemic sclerosis.

Harvey GR, Butts S, Rands AL, Patel Y, McHugh NJ.

Clin Exp Immunol. 1999 Aug;117(2):395-402.

9.

Antibodies to fibrillarin, PM-Scl and RNA polymerase III detected by ELISA assays in patients with systemic sclerosis.

Villalta D, Morozzi G, Tampoia M, Alpini C, Brusca I, Salgarolo V, Papisch W, Bizzaro N.

Clin Chim Acta. 2010 May 2;411(9-10):710-3. doi: 10.1016/j.cca.2010.01.037.

PMID:
20138166
10.

[Autoantibodies and their clinical characteristics in systemic sclerosis].

Hamaguchi Y.

Nihon Rinsho Meneki Gakkai Kaishi. 2013;36(3):139-47. Review. Japanese.

11.

Autoantibody profiles in systemic sclerosis: predictive value for clinical evaluation and prognosis.

Hamaguchi Y.

J Dermatol. 2010 Jan;37(1):42-53. doi: 10.1111/j.1346-8138.2009.00762.x. Review.

PMID:
20175839
12.

Serological profile of patients with systemic sclerosis.

Wielosz E, Dryglewska M, Majdan M.

Postepy Hig Med Dosw (Online). 2014 Aug 18;68:987-91. doi: 10.5604/17322693.1117543.

13.

Anti-CENP-B response in sera of uranium miners exposed to quartz dust and patients with possible development of systemic sclerosis (scleroderma).

Conrad K, Stahnke G, Liedvogel B, Mehlhorn J, Barth J, Blasum C, Altmeyer P, Sönnichsen N, Frank KH.

J Rheumatol. 1995 Jul;22(7):1286-94.

PMID:
7562760
14.

Distinctive autoantibody profile in Mexican Mestizo systemic sclerosis patients.

Rodriguez-Reyna TS, Hinojosa-Azaola A, Martinez-Reyes C, Nuñez-Alvarez CA, Torrico-Lavayen R, García-Hernández JL, Cabiedes-Contreras J.

Autoimmunity. 2011 Nov;44(7):576-84. doi: 10.3109/08916934.2011.592886.

PMID:
21875377
15.

Specific anti-nuclear antibodies in systemic sclerosis patients with and without skin involvement: an extended methodological approach.

Van Praet JT, Van Steendam K, Smith V, De Bruyne G, Mimori T, Bonroy C, Elewaut D, Deforce D, De Keyser F.

Rheumatology (Oxford). 2011 Jul;50(7):1302-9. doi: 10.1093/rheumatology/keq446.

PMID:
21330340
16.

Differences in autoantibody response to Th/To between systemic sclerosis and other autoimmune diseases.

Kuwana M, Kimura K, Hirakata M, Kawakami Y, Ikeda Y.

Ann Rheum Dis. 2002 Sep;61(9):842-6.

17.

Atypical clinical presentation of a subset of patients with anti-RNA polymerase III--non-scleroderma cases associated with dominant RNA polymerase I reactivity and nucleolar staining.

Ceribelli A, Krzyszczak ME, Li Y, Ross SJ, Chan JY, Chan EK, Burlingame RW, Webb TT, Bubb MR, Sobel ES, Reeves WH, Satoh M.

Arthritis Res Ther. 2011 Jul 22;13(4):R119. doi: 10.1186/ar3422.

18.

Clinical and serological evaluation of a novel CENP-A peptide based ELISA.

Mahler M, Maes L, Blockmans D, Westhovens R, Bossuyt X, Riemekasten G, Schneider S, Hiepe F, Swart A, Gürtler I, Egerer K, Fooke M, Fritzler MJ.

Arthritis Res Ther. 2010;12(3):R99. doi: 10.1186/ar3029.

20.

Anticentromere autoantibodies in patients without Raynaud's disease or systemic sclerosis.

Vázquez-Abad D, Grodzicky T, Senécal JL.

Clin Immunol. 1999 Feb;90(2):182-9.

PMID:
10080829

Supplemental Content

Support Center